Literature DB >> 1838363

Phase II evaluation of menogaril in patients with advanced hypernephroma.

H J Long1, M D Hauge, T M Therneau, J C Buckner, S Frytak, R G Hahn.   

Abstract

Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1838363     DOI： 10.1007/bf00176980

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  10 in total

1.  Intracellular uptake of 7-con-o-methylnogarol and adriamycin by cells in culture and its relationship to cell survival.

Authors:  B K Bhuyan; J P McGovren; S L Crampton
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

2.  Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 leukemia.

Authors:  L H Li; S L Kuentzel; L L Murch; L M Pschigoda; W C Krueger
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

3.  Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent.

Authors:  J P McGovren; G L Neil; R H Denlinger; T L Hall; S L Crampton; J A Swenberg
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

4.  Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

Authors:  R G Hahn; M Bauer; J Wolter; R Creech; J M Bennett; G Wampler
Journal:  Cancer Treat Rep       Date:  1979-03

5.  Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma.

Authors:  D S Poster; S Bruno; J S Penta; K Pinna; P Vilk; J S Macdonald
Journal:  Am J Clin Oncol       Date:  1982-02       Impact factor: 2.339

6.  Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.

Authors:  H I Scher; A Yagoda; T Ahmed; D Budman; P Sordillo; R C Watson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.

Authors:  M J Egorin; D A Van Echo; M Y Whitacre; A Forrest; L M Sigman; K L Engisch; J Aisner
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

8.  Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.

Authors:  G L Neil; S L Kuentzel; J P McGovren
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

9.  Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.

Authors:  H J Long; G Powis; A J Schutt; C G Moertel
Journal:  Cancer Treat Rep       Date:  1987-06

10.  Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells.

Authors:  E G Adams; S L Crampton; B K Bhuyan
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701
  10 in total
  1 in total

1.  The last dicynodont: an Australian Cretaceous relict.

Authors:  Tony Thulborn; Susan Turner
Journal:  Proc Biol Sci       Date:  2003-05-07       Impact factor: 5.349
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.